Table of Contents
List of Tables 4
List of Figures 5
Report Guidance 6
GlobalData Clinical Trials Report Coverage 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
Top Five Countries Contributing to Clinical Trials in Europe 13
Top Countries Contributing to Clinical Trials in North America 14
Top Countries Contributing to Clinical Trials in Middle East and Africa 15
Top Countries Contributing to Clinical Trials in Central and South America 16
Clinical Trials by G7 Countries: Proportion of Attention Deficit Hyperactivity Disorder (ADHD) to Central Nervous System Clinical Trials 17
Clinical Trials by Phase in G7 Countries 19
Clinical Trials in G7 Countries by Trial Status 20
Clinical Trials by E7 Countries: Proportion of Attention Deficit Hyperactivity Disorder (ADHD) to Central Nervous System Clinical Trials 21
Clinical Trials by Phase in E7 Countries 23
Clinical Trials in E7 Countries by Trial Status 24
Clinical Trials by Phase 25
In Progress Trials by Phase 26
Clinical Trials by Trial Status 27
Clinical Trials by End Point Status 28
Subjects Recruited Over a Period of Time 29
Clinical Trials by Sponsor Type 30
Prominent Sponsors 31
Top Companies Participating in Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials 33
Prominent Drugs 34
Latest Clinical Trials News on Attention Deficit Hyperactivity Disorder (ADHD) 35
Nov 11, 2019: Supernus submits New Drug Application for SPN-812 for the treatment of ADHD 35
Nov 05, 2019: Supernus Pharmaceuticals announces data from phase III study of SPN-810 for treatment of Impulsive Aggression (IA) in ADHD patients 35
Nov 04, 2019: Ironshore to present data from a pivotal trial of JORNAY PM (methylphenidate HCl) CII at the 31st Annual International Conference on ADHD 35
Oct 22, 2019: KemPharm presents study highlighting patient-friendly dosing properties of KP415 at the 66th Annual American Academy of Child & Adolescent Psychiatry Meeting 36
Oct 16, 2019: Ironshore Pharmaceuticals to present data at the 66th Annual AACAP Meeting 36
Oct 04, 2019: Oryzon reveals positive data from anti-aggression drug vafidemstat 37
Sep 23, 2019: ORYZON presents new data on vafidemstat 37
Clinical Trial Profile Snapshots 39
Appendix 821
Abbreviations 821
Definitions 821
Research Methodology 822
Secondary Research 822
About GlobalData 823
Contact Us 823
Source 824
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials by Region, 2019* 8
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 10
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 11
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2019* 12
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Europe, Top Five Countries, 2019* 13
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, North America, Top Countries, 2019* 14
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2019* 15
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Central and South America, Top Countries, 2019* 16
Proportion of Attention Deficit Hyperactivity Disorder (ADHD) to Central Nervous System Clinical Trials, G7 Countries (%), 2019* 18
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 19
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 20
Proportion of Attention Deficit Hyperactivity Disorder (ADHD) to Central Nervous System Clinical Trials, E7 Countries (%), 2019* 22
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 23
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 24
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials by Phase, 2019* 25
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials In Progress by Phase 2019* 26
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials by Trial Status, 2019* 27
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, by End Point Status, 2019* 28
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 29
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019* 30
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 32
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 33
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 34
List of Figures
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials by Region (%), 2019* 8
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 9
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 11
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2019* 12
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019* 13
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, North America, Top Countries (%), 2019* 14
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2019* 15
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2019* 16
Proportion of Attention Deficit Hyperactivity Disorder (ADHD) to Central Nervous System Clinical Trials, G7 Countries (%), 2019* 17
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 19
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 20
Proportion of Attention Deficit Hyperactivity Disorder (ADHD) to Central Nervous System Clinical Trials, E7 Countries (%), 2019* 21
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 23
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 24
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials by Phase (%), 2019* 25
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials In Progress by Phase, 2019* 26
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials by Trial Status, 2019* 27
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, by End Point Status, 2019* 28
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 29
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019* 30
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 31
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 33
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 34
GlobalData Methodology 822
【免責事項】
https://www.marketreport.jp/reports-disclaimer